3-Ethyl 1-tert-butyl 3-(2-cyanoethyl)piperidine-1,3-dicarboxylate | 923009-53-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-Ethyl 1-tert-butyl 3-(2-cyanoethyl)piperidine-1,3-dicarboxylate
• 英文别名: 1-O-tert-butyl 3-O-ethyl 3-(2-cyanoethyl)piperidine-1,3-dicarboxylate
• CAS: 923009-53-4
• 化学式: C₁₆H₂₆N₂O₄
• 分子量: 310.393
• InChiKey: MILDNACITZFYRT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.81
• 拓扑面积：
  79.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-Ethyl 1-tert-butyl 3-(2-cyanoethyl)piperidine-1,3-dicarboxylate 在 盐酸 、 氨 、 水 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 水 、 乙酸乙酯 为溶剂， 60.0 ℃ 、500.01 kPa 条件下， 生成 2-Ethyl-2,8-diazaspiro[5.5]undecan-1-one
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors

  摘要：

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.117
• 作为产物：
  描述：

  3-溴丙腈 、 N-Boc-3-哌啶甲酸乙酯 以the title compound (3.85 g, yield 32%) was obtained as an oil by an operation similar to that of Reference Example 1的产率得到3-Ethyl 1-tert-butyl 3-(2-cyanoethyl)piperidine-1,3-dicarboxylate
  参考文献：
  名称：

  SPIRO-CYCLIC COMPOUND

  摘要：

  本发明提供了一种由公式(I)表示的化合物：其中E是可选取代的环状基团；D是羰基基团或磺酰基团；A是CH或N；环P是可选取代的5-至7-成员环；环Q是可选取代的5-至7-成员非芳香环；环R是可选取代和可选缩合的5-至7-成员非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于预防或治疗肥胖症、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等疾病有用，并具有优越的疗效、活性持续时间、特异性、低毒性等特点。

  公开号：

  US20100160255A1

文献信息

• SPIRO-CYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911753A1

  公开（公告）日：2008-04-16

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中 E是一个可选择地取代的环状基团； D是一个羰基团或磺酰基团； A是CH或N； 环P是一个可选择进一步取代的5至7元环； 环Q是一个可选择进一步取代的5至7元非芳香环； 环R是一个可选择进一步取代和可选择缩合的5至7元非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等的预防或治疗具有用处，并且在功效、持续活性、特异性、低毒性等方面具有优越性能。
• Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors
  作者：Tohru Yamashita、Makoto Kamata、Satoshi Endo、Mitsuo Yamamoto、Keiko Kakegawa、Hiroyuki Watanabe、Katsuhiko Miwa、Toru Yamano、Masaaki Funata、Jyun-ichi Sakamoto、Akiyoshi Tani、Clifford D. Mol、Hua Zou、Douglas R. Dougan、BiChing Sang、Gyorgy Snell、Kohji Fukatsu

  DOI：10.1016/j.bmcl.2011.08.117

  日期：2011.11

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.